tbuckley/cabot-search huggingface dataset:
Persistence of Risk for Type 2 Diabetes After Gestational Diabetes Mellitus
Authors: Mary V. Diaz-Santana, Katie M. O’Brien, Yong-Moon Mark Park, Dale P. Sandler, Clarice R. Weinberg
Journal: Diabetes Care (2022)

OBJECTIVE Gestational diabetes mellitus complicates ∼6% of pregnancies and strongly predicts subsequent type 2 diabetes. It has not been fully elucidated how risk depends on the number of affected pregnancies or how long the excess risk persists. RESEARCH DESIGN AND METHODS We assessed reproductive histories in relation to risk of type 2 diabetes using a nationwide cohort of 50,884 women. Among participants who initially did not have diabetes, 3,370 were diagnosed with diabetes during 10 years of follow-up. We used Cox proportional hazards models that allowed risk to depend on age, cumulative number of pregnancies with gestational diabetes mellitus, and time since the most recent affected pregnancy, adjusting for BMI, educational level, and race/ethnicity. RESULTS History of one or more pregnancies with gestational diabetes mellitus predicted elevated age-specific risk of type 2 diabetes, with a hazard ratio of 3.87 (95% CI 2.60–5.75) 6–15 years after an affected pregnancy. Risk increased steeply with multiple affected pregnancies. The age-specific associations attenuated over time after an affected pregnancy, with an estimated 24% reduction of the hazard ratio per decade. Risk remained elevated, however, for &amp;gt;35 years. CONCLUSIONS Gestational diabetes mellitus predicted markedly increased rates of type 2 diabetes. Relative risk increased substantially with each additional affected pregnancy. The estimated hazard ratio declined with time after a pregnancy with gestational diabetes mellitus but remained elevated for &amp;gt;35 years. Women recalling a history of gestational diabetes mellitus should be screened regularly for type 2 diabetes, even late in life.
“Functional ageing in fibrotic interstitial lung disease: the impact of frailty on adverse health outcomes.” Sabina A. Guler, Joanne M. Kwan, Janice M. Leung, Nasreen Khalil, Pearce G. Wilcox and Christopher J. Ryerson. <i>Eur Respir J</i> 2020; 55: 1900647.
Journal: European Respiratory Journal (2020)

Figures 1 and 2 in this article were published with the incorrect frailty index definitions for “frail” and “non-frail” subjects (in the key to the figures). Frail subjects were incorrectly defined as those with frailty index ≤0.21, and non-frail subjects with frailty index >0.21. The correct definitions of frail and non-frail subjects are those with frailty index >0.21 and ≤0.21, respectively, as presented in the amended figures below.
Corrigendum: Role of yes‐associated protein in interleukin‐13 induced nasal remodeling of chronic rhinosinusitis with nasal polyps
Authors: Tian Yuan, Rui Zheng, Jing Liu, Kai Sen Tan, Zhi‐qun Huang, Xiang‐Min Zhou, Xiao‐xue Zi, Hui‐jun Qiu, Xin‐yue Wang, Wei‐hao Wang, Hui‐yi Deng, Yu‐bin Chen, Wei‐feng Kong, Qing‐wu Wu, Ying Huang, Hsiao Hui Ong, Xue‐kun Huang, Zhuang‐gui Chen, De‐Yun Wang, Qin‐Tai Yang
Journal: Allergy (2022)

To Editor: In Feb 2021, we published a letter titled "Role of yes-associated protein in interleukin-13 induced nasal remodeling of chronic rhinosinusitis with nasal polyps" in Allergy (PMID: 33301614; 10.1111/all.14699). Recently, an error was spotted in the typesetting figures of this letter that likely occurred during the revision of the paper. In Fig 2 (I), a wrong image is inserted in the place of the original, correct figure when we are revising the manuscript following peer review. As a result, the immunofluorescence image of MUC5AC and YAP labeled "D24: IL-13+VP" is a duplicate of Fig 1(T) picture labeled "D24 CTRL" (Figure 1). We would like to emphasize, however, that this error did not affect the results and conclusion of the article as the error stemmed from misplacing of the IF image at the wrong grouping column during the preparation of the manuscript revision. We apologize for the oversight when checking the manuscript during revision which impacted the journal and caused confusion to the readers. This mistake serves as a lesson to be doubly rigorous and careful in preparing and vetting manuscripts, especially when many subfigures are involved. We sincerely apologize to the journal and readers of the journal. We have now corrected the error in the article. In this corrigendum to the original article, we have included a revised Fig 2 (I) with the right staining image as shown in this corrigendum (Figure 2), to address the error in the original article. The authors have no conflicts of interest to declare. All the authors are aware of the mistake and approve of the amendment.
A programmed surface on polyetheretherketone for sequentially dictating osteoimmunomodulation and bone regeneration to achieve ameliorative osseointegration under osteoporotic conditions
Authors: Yanyan Zheng, Ang Gao, Jiaxiang Bai, Qing Liao, Yuzheng Wu, Wei Zhang, Min Guan, Liping Tong, Dechun Geng, Xin Zhao, Paul K. Chu, Huaiyu Wang
Journal: Bioactive Materials (2022)

Polyetheretherketone (PEEK) is a desirable alternative to conventional biomedical metals for orthopedic implants due to the excellent mechanical properties. However, the inherent bioinertness of PEEK contributes to inferior osseointegration of PEEK implants, especially under pathological conditions of osteoporosis. Herein, a programmed surface is designed and fabricated on PEEK to dictate osteoimmunomodulation and bone regeneration sequentially. A degradable hybrid coating consisting of poly(lactide-co-glycolide) and alendronate (ALN) loaded nano-hydroxyapatite is deposited on PEEK and then interleukin-4 (IL-4) is grafted onto the outer surface of the hybrid coating with the aid of N2 plasma immersion ion implantation and subsequent immersion in IL-4 solution. Dominant release of IL-4 together with ALN and Ca2+ during the first few days synergistically mitigates the early acute inflammatory reactions and creates an osteoimmunomodulatory microenvironment that facilitates bone regeneration. Afterwards, slow and sustained delivery of ALN and Ca2+ in the following weeks boosts osteogenesis and suppresses osteoclastogenesis simultaneously, consequently ameliorating bone-implant osseointegration even under osteoporotic conditions. By taking into account the different phases in bone repair, this strategy of constructing advanced bone implants with sequential functions provides customizable and clinically viable therapy to osteoporotic patients.
A Phase III Double-Masked, Crossover, Vehicle-Controlled Clinical Trial Conducted in an Environmental Exposure Chamber (EEC) to Study Reproxalap, a Novel, Non-Antihistaminic, Non-Steroidal, Reactive Aldehyde Species Inhibitor for the Treatment for Allergic Conjunctivitis (AC)
Authors: Anne Marie Salapatek, Yasmeen Goyal, Saili Bundele, Todd Brady, Peter Couroux
Journal: Journal of Allergy and Clinical Immunology (2022)
Corrigendum to “589P Dynamics of peripheral blood immune profiling associated with tumour progression in metastatic castration resistant prostate cancer (mCRPC)”
Authors: E. Perez-Navarro, V. Conteduca, A. González-del-Alba, B. Mellado, P. Cremaschi, O. Fernandez-Calvo, M.J. Méndez-Vidal, M.A. Climent, I. Duran, A. Font, M.P. Fernandez-Perez, A. Martínez, M.J. López-Andreo, G. Attard, D. Castellano, E. Grande, U. de Giorgi, J.A. Botia, J.T. Palma Méndez, E. Gonzalez-Billalabeitia
Journal: Annals of Oncology (2022)
Contrast‐enhanced CT and liver surface nodularity for the diagnosis of porto‐sinusoidal vascular disorder: A case‐control study
Authors: Shantha Ram Valainathan, Riccardo Sartoris, Laure Elkrief, Marta Magaz, Fabian Betancourt, Silvia Pellegrino, Arianna Nivolli, Marco Dioguardi Burgio, Yves Flattet, Sylvain Terraz, Nicolas Drilhon, Marie Lazareth, Julia Herrou, Onorina Bruno, Audrey Payance, Aurélie Plessier, François Durand, Maxime Ronot, Dominique‐Charles Valla, Valérie Paradis, Juan Carlos Garcia‐Pagan, Valérie Vilgrain, Pierre‐Emmanuel Rautou
Journal: Hepatology (2022)

Porto-sinusoidal vascular disorder (PSVD) is a rare and commonly overlooked cause of portal hypertension. The interest of CT analysis, including quantification of liver surface nodularity (LSN) for PSVD diagnosis has not been established. This study aimed at assessing the performance of LSN and CT features for a PSVD diagnosis in patients with signs of portal hypertension.This retrospective case-control study included a learning cohort consisting of 50 patients with histologically proven PSVD, according to VALDIG criteria, and 100 control patients with histologically proven cirrhosis, matched on ascites. All patients and controls had at least one sign of portal hypertension and CT available within 1 year of liver biopsy. Principal component analysis of CT features separated patients with PSVD from patients with cirrhosis. Patients with PSVD had lower median LSN than those with cirrhosis (2.4 vs. 3.1, p < 0.001). Multivariate analysis identified LSN < 2.5 and normal-sized or enlarged segment IV as independently associated with PSVD. Combination of these two features had a specificity of 90% for PSVD and a diagnostic accuracy of 84%. Even better results were obtained in an independent multicenter validation cohort including 53 patients with PSVD and 106 control patients with cirrhosis (specificity 94%, diagnostic accuracy 87%).This study that included a total of 103 patients with PSVD and 206 patients with cirrhosis demonstrates that LSN < 2.5 combined with normal-sized or enlarged segment IV strongly suggests PSVD in patients with signs of portal hypertension.
p21‐activated kinase 4 inhibition protects against liver ischemia/reperfusion injury: Role of nuclear factor erythroid 2‐related factor 2 phosphorylation
Authors: Yuancheng Mao, Chang Yeob Han, Lihua Hao, Younho Lee, Jung Beom Son, Hwangeun Choi, Mi Rin Lee, Jae Do Yang, Suk Kyun Hong, Kyung‐Suk Suh, Hee Chul Yu, Nam Doo Kim, Eun Ju Bae, Byung‐Hyun Park
Journal: Hepatology (2022)

Abstract Background and Aims p21‐activated kinase 4 (PAK4), an oncogenic protein, has emerged as a promising target for anticancer drug development. Its role in oxidative stress conditions, however, remains elusive. We investigated the effects of PAK4 signaling on hepatic ischemia/reperfusion (I/R) injury. Approach and Results Hepatocyte‐ and myeloid‐specific Pak4 knockout (KO) mice and their littermate controls were subjected to a partial hepatic I/R (HIR) injury. We manipulated the catalytic activity of PAK4, either through genetic engineering (gene knockout, overexpression of wild‐type [WT] or dominant‐negative kinase) or pharmacological inhibitor, coupled with a readout of nuclear factor erythroid 2‐related factor 2 (Nrf2) activity, to test the potential function of PAK4 on HIR injury. PAK4 expression was markedly up‐regulated in liver during HIR injury in mice and humans. Deletion of PAK4 in hepatocytes, but not in myeloid cells, ameliorated liver damages, as demonstrated in the decrease in hepatocellular necrosis and inflammatory responses. Conversely, the forced expression of WT PAK4 aggravated the pathological changes. PAK4 directly phosphorylated Nrf2 at T369, and it led to its nuclear export and proteasomal degradation, all of which impaired antioxidant responses in hepatocytes. Nrf2 silencing in liver abolished the protective effects of PAK4 deficiency. A PAK4 inhibitor protected mice from HIR injury. Conclusions PAK4 phosphorylates Nrf2 and suppresses its transcriptional activity. Genetic or pharmacological suppression of PAK4 alleviates HIR injury. Thus, PAK4 inhibition may represent a promising intervention against I/R‐induced liver injury.
Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.
Authors: L Stewart, K Aabo, P Adnitt, M Adams, S Alberts, V Barley, D Bell, U Bianchi, J Blessing, M Buyse, G Bolis, S Brodovsky, H Bruckner, R Canetta, V Chylak, J Cohen, N Colombo, F Conte, D Crowther, F De Oliveira, J Edmonson, E Gilbey, S Kaye, A Laing, F Landoni, R Leonard, C Lewis, Y Liu, C Mangioni, S Marsoni, H Meerpohl, U Muller, G Omura, K Parmar, J Pater, S Pecorelli, M Presti, W Sauerbrei, R Smalley, J Solomon, J Sturgeon, H Tattersall, J Wharton, W Ten, Bokkel Huinink, M Tomirotti, W Torri, C Trope, M Turbow, J Vermorken, M Webb, W Wilbur, J Williams, Ctx Cbdsa
Journal: BMJ (1991)

OBJECTIVES--To consider the role of platinum and the relative merits of single agent and combination chemotherapy in the treatment of advanced ovarian cancer. DESIGN--Formal quantitative overview using updated individual patient data from all available randomised trials (published and unpublished). SUBJECTS--8139 patients (6408 deaths) included in 45 different trials. RESULTS--No firm conclusions could be reached. Nevertheless, the results suggest that in terms of survival immediate platinum based treatment was better than non-platinum regimens (overall relative risk 0.93; 95% confidence interval 0.83 to 1.05); platinum in combination was better than single agent platinum when used in the same dose (overall relative risk 0.85; 0.72 to 1.00); and cisplatin and carboplatin were equally effective (overall relative risk 1.05; 0.94 to 1.18). CONCLUSIONS--In the past, randomised clinical trials of chemotherapy in advanced ovarian cancer have been much too small to detect the degree of benefit which this overview suggests is realistic for currently available chemotherapeutic regimens. Hence a new trial comparing cisplatin, doxorubicin, and cyclophosphamide (CAP) with carboplatin has been launched and plans to accrue 2000 patients.
Host Adaptation in<i>Legionellales</i>Is 1.9 Ga, Coincident with Eukaryogenesis
Authors: Eric Hugoson, Andrei Guliaev, Tea Ammunét, Lionel Guy
Journal: Molecular Biology and Evolution (2022)

Abstract Bacteria adapting to living in a host cell caused the most salient events in the evolution of eukaryotes, namely the seminal fusion with an archaeon, and the emergence of both mitochondrion and chloroplast. A bacterial clade that may hold the key to understanding these events is the deep-branching gammaproteobacterial order Legionellales—containing among others Coxiella and Legionella—of which all known members grow inside eukaryotic cells. Here, by analyzing 35 novel Legionellales genomes mainly acquired through metagenomics, we show that this group is much more diverse than previously thought, and that key host-adaptation events took place very early in its evolution. Crucial virulence factors like the Type IVB secretion (Dot/Icm) system and two shared effector proteins were gained in the last Legionellales common ancestor (LLCA). Many metabolic gene families were lost in LLCA and its immediate descendants, including functions directly and indirectly related to molybdenum metabolism. On the other hand, genome sizes increased in the ancestors of the Legionella genus. We estimate that LLCA lived approximately 1.89 Ga, probably predating the last eukaryotic common ancestor by approximately 0.4–1.0 Gy. These elements strongly indicate that host adaptation arose only once in Legionellales, and that these bacteria were using advanced molecular machinery to exploit and manipulate host cells early in eukaryogenesis.
Obituary Listing
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
USAN assigned to radioactive pharmaceuticals
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial
Authors: Jingxin Li, Lihua Hou, Xiling Guo, Pengfei Jin, Shipo Wu, Jiahong Zhu, Hongxing Pan, Xue Wang, Zhizhou Song, Jingxuan Wan, Lunbiao Cui, Junqiang Li, Yin Chen, Xuewen Wang, Lairun Jin, Jingxian Liu, Fengjuan Shi, Xiaoyu Xu, Tao Zhu, Wei Chen, Fengcai Zhu
Journal: Nature Medicine (2022)

Abstract The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and the waning of vaccine-elicited neutralizing antibodies suggests that additional coronavirus disease 2019 (COVID-19) vaccine doses may be needed for individuals who initially received CoronaVac. We evaluated the safety and immunogenicity of the recombinant adenovirus type 5 (AD5)-vectored COVID-19 vaccine Convidecia as a heterologous booster versus those of CoronaVac as homologous booster in adults previously vaccinated with CoronaVac in an ongoing, randomized, observer-blinded, parallel-controlled phase 4 trial ( NCT04892459 ). Adults who had received two doses of CoronaVac in the past 3–6 months were vaccinated with Convidecia ( n = 96) or CoronaVac ( n = 102). Adults who had received one dose of CoronaVac in the past 1–3 months were also vaccinated with Convidecia ( n = 51) or CoronaVac ( n = 50). The co-primary endpoints were the occurrence of adverse reactions within 28 d after vaccination and geometric mean titers (GMTs) of neutralizing antibodies against live wild-type SARS-CoV-2 virus at 14 d after booster vaccination. Adverse reactions after vaccination were significantly more frequent in Convidecia recipients but were generally mild to moderate in all treatment groups. Heterologous boosting with Convidecia elicited significantly increased GMTs of neutralizing antibody against SARS-CoV-2 than homologous boosting with CoronaVac in participants who had previously received one or two doses of CoronaVac. These data suggest that heterologous boosting with Convidecia following initial vaccination with CoronaVac is safe and more immunogenic than homologous boosting.
Correction: Smoking and leukaemia
Authors: Jane Salvage
Journal: BMJ (1989)

light of this further evidence of its harmful effects on the quality of patient care.Furthermore, the research suggests a wealth of barely tapped potential among NHS ancillary staff.Those who are content with their jobs should be helped to do them in a satisfying way, but others who could move into more demanding roles should be offered training and development opportunities.Possibilities already exist here - for example, Workbase is a trade union project backed by the NHS Training Authority that promotes and provides training for manual workers.3Another option is experimenting with new roles such as care assistant which combine domestic and nursing responsibilities.'Most striking of all, however, is an implicit lesson that is relevant to everyone in the NHS.Better standards of care may be achieved only by highly motivated staff in all types of work and at all levels in the organisation.The way to encourage people to care more about their work is to care more about them, whether they are a cleaner or a consultant.
Immune profile and responses of a novel dengue DNA vaccine encoding an EDIII-NS1 consensus design based on Indo-African sequences
Authors: Arun Sankaradoss, Suraj Jagtap, Junaid Nazir, Shefta E. Moula, Ayan Modak, Joshuah Fialho, Meenakshi Iyer, Jayanthi S. Shastri, Mary Dias, Ravisekhar Gadepalli, Alisha Aggarwal, Manoj Vedpathak, Sachee Agrawal, Awadhesh Pandit, Amul Nisheetha, Anuj Kumar, Mahasweta Bordoloi, Mohamed Shafi, Bhagyashree Shelar, Swathi S. Balachandra, Tina Damodar, Moses Muia Masika, Patrick Mwaura, Omu Anzala, Kar Muthumani, Ramanathan Sowdhamini, Guruprasad R. Medigeshi, Rahul Roy, Chitra Pattabiraman, Sudhir Krishna, Easwaran Sreekumar
Journal: Molecular Therapy (2022)

The ongoing COVID-19 pandemic highlights the need to tackle viral variants, expand the number of antigens, and assess diverse delivery systems for vaccines against emerging viruses. In the present study, a DNA vaccine candidate was generated by combining in tandem envelope protein domain III (EDIII) of dengue virus serotypes 1-4 and a dengue virus (DENV)-2 non-structural protein 1 (NS1) protein-coding region. Each domain was designed as a serotype-specific consensus coding sequence derived from different genotypes based on the whole genome sequencing of clinical isolates in India and complemented with data from Africa. This sequence was further optimized for protein expression. In silico structural analysis of the EDIII consensus sequence revealed that epitopes are structurally conserved and immunogenic. The vaccination of mice with this construct induced pan-serotype neutralizing antibodies and antigen-specific T cell responses. Assaying intracellular interferon (IFN)-γ staining, immunoglobulin IgG2(a/c)/IgG1 ratios, and immune gene profiling suggests a strong Th1-dominant immune response. Finally, the passive transfer of immune sera protected AG129 mice challenged with a virulent, non-mouse-adapted DENV-2 strain. Our findings collectively suggest an alternative strategy for dengue vaccine design by offering a novel vaccine candidate with a possible broad-spectrum protection and a successful clinical translation either as a stand alone or in a mix and match strategy.
Are skin microbes with lantibiotic biosynthesis genes reduced in atopic dermatitis subjects who are culture positive for Staphylococcus aureus?
Authors: Jessica Forman, Takeshi Yoshida, Jacquelyn Lillis, Ann Gill, Anthony Corbett, Michael Cahill, Eric Simpson, Mark Boguniewicz, Jon Hanifin, Anna De Benedetto, Gloria David, Donald Leung, Patrick Schlievert, steven gill, Lisa Beck
Journal: Journal of Allergy and Clinical Immunology (2022)